Predictive role of C677T MTHFR polymorphism in variable efficacy of photodynamic therapy for neovascular age-related macular degeneration. (Q37356525)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19102718%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

review article

1 reference

title

Predictive role of C677T MTHFR polymorphism in variable efficacy of photodynamic therapy for neovascular age-related macular degeneration (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19102718%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19102718%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Ciro Costagliola

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19102718%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

author name string

Francesco Parmeggiani

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19102718%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Adolfo Sebastiani

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19102718%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Carlo Incorvaia

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19102718%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

publication date

1 January 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19102718%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19102718%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

volume

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19102718%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

page(s)

81-95

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19102718%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19102718%20AND%20SRC:MED&resulttype=core&format=json

The epidemiology of age-related macular degeneration

19 January 2020

cites work

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.81

Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization--verteporfin in photodynami

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.81

Guidelines for using verteporfin (Visudyne) in photodynamic therapy for choroidal neovascularization due to age-related macular degeneration and other causes: update

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.81

Evolving European guidance on the medical management of neovascular age related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.81

The natural history and prognosis of neovascular age-related macular degeneration: a systematic review of the literature and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.81

Occult choroidal neovascularization in age-related macular degeneration. A natural history study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.81

CNV subtype in first eyes predicts severity of ARM in fellow eyes.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.81

A preliminary benefit-risk assessment of verteporfin in age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.81

Pegaptanib for neovascular age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.81

Ranibizumab for neovascular age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.81

Ranibizumab versus verteporfin for neovascular age-related macular degeneration.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.81

Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: a one-year prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.81

Antivascular endothelial growth factor agents and their development: therapeutic implications in ocular diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.81

The evolving role of vascular endothelial growth factor inhibitors in the treatment of neovascular age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.81

Rationale for combination therapies for choroidal neovascularization

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.81

Synergies of VEGF inhibition and photodynamic therapy in the treatment of age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.81

Combination therapy for the treatment of ocular neovascularization

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.81

Management of neovascular age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.81

Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration (FOCUS): year 2 results

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.81

Ranibizumab and pegaptanib for the treatment of age-related macular degeneration: a systematic review and economic evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.81

A value-based medicine analysis of ranibizumab for the treatment of subfoveal neovascular macular degeneration.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.81

A value-based medicine comparison of interventions for subfoveal neovascular macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.81

Ranibizumab (Lucentis) versus bevacizumab (Avastin): modelling cost effectiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.81

Targeting vascular endothelial growth factor: a promising strategy for treating age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.81

Economic burden of bilateral neovascular age-related macular degeneration: multi-country observational study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.81

How does photodynamic therapy work?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.81

Mechanisms of action of photodynamic therapy with verteporfin for the treatment of age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.81

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.81

Sequence of Early Vascular Events after Photodynamic Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.81

Time course and morphology of vascular effects associated with photodynamic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.81

Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration: 2-year results of a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.81

Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP report no. 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.81

Photodynamic therapy for age-related macular degeneration in a clinical setting: visual results and angiographic patterns

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.81

Impact of lesion size on photodynamic therapy with verteporfin of predominantly classic lesions in age related macular degeneration.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.81

Factors influencing poor visual outcome in patients treated with photodynamic therapy for choroidal neovascularization secondary to age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.81

Photodynamic therapy in macular diseases of asian populations: when East meets West

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.81

Review of first year result of photodynamic therapy on age-related macular degeneration in Chinese population

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.81

Photodynamic therapy in practice: a review of the results of the first 12 months experience with verteporfin at the Royal Victorian Eye and Ear Hospital.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.81

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.81

Outcomes in verteporfin photodynamic therapy for choroidal neovascularisation--'beyond the TAP study'.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.81

Verteporfin therapy in age-related macular degeneration (VAM): an open-label multicenter photodynamic therapy study of 4,435 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.81

12-month retrospective study and review of photodynamic therapy with verteporfin for subfoveal choroidal neovascularization in age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.81

Photodynamic therapy of subfoveal choroidal neovascularization: clinical and angiographic examples

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.81

Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of a single treatment in a phase 1 and 2 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.81

Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of retreatments in a phase 1 and 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.81

Verteporfin therapy of subfoveal occult choroidal neovascularization in AMD using delayed light application: one-year results of the VALIO Study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.81

Randomized multicenter trial of more intense and standard early verteporfin treatment of neovascular age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.81

Predictive role of coagulation-balance gene polymorphisms in the efficacy of photodynamic therapy with verteporfin for classic choroidal neovascularization secondary to age-related macular degeneration.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.81

Coagulation gene predictors of photodynamic therapy for occult choroidal neovascularization in age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.81

Modulation of thrombophilia genes by environmental factors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.81

Seven haemostatic gene polymorphisms in coronary disease: meta-analysis of 66,155 cases and 91,307 controls.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.81

Factor V Leiden: a disorder of factor V anticoagulant function

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.81

3' end processing of the prothrombin mRNA in thrombophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.81

Role of factor XIII in fibrin clot formation and effects of genetic polymorphisms

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.81

No Val34Leu polymorphism of the gene for factor XIIIA subunit was detected by ARMS-RACE method in three Asian populations

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.81

The combined effect of fibrin formation and factor XIII A subunit Val34Leu polymorphism on the activation of factor XIII in whole plasma.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.81

Homocysteine, coagulation, platelet function, and thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.81

Polymorphisms in the methylenetetrahydrofolate reductase gene: clinical consequences

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.81

The frequent 5,10-methylenetetrahydrofolate reductase C677T polymorphism is associated with a common haplotype in whites, Japanese, and Africans

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.81

Gene-gene and gene-environment interactions in mild hyperhomocysteinemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.81

Homocysteine metabolism, hyperhomocysteinaemia and vascular disease: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.81

Defects in homocysteine metabolism: diversity among hyperhomocyst(e)inemias

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.81

Methylenetetrahydrofolate reductase gene polymorphisms in 13 Chinese ethnic populations

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.81

Methylenetetrahydrofolate reductase C677T and A1298C gene variants in adult non-Hodgkin's lymphoma patients: association with toxicity and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.81

Effects of common polymorphisms on the properties of recombinant human methylenetetrahydrofolate reductase

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.81

Geographical and ethnic variation of the 677C>T allele of 5,10 methylenetetrahydrofolate reductase (MTHFR): findings from over 7000 newborns from 16 areas world wide

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.81

Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.81

Mice deficient in methylenetetrahydrofolate reductase exhibit hyperhomocysteinemia and decreased methylation capacity, with neuropathology and aortic lipid deposition

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.81

Endothelial cell injury due to copper-catalyzed hydrogen peroxide generation from homocysteine

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.81

Endothelial dysfunction in a murine model of mild hyperhomocyst(e)inemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.81

Demonstration of rapid onset vascular endothelial dysfunction after hyperhomocysteinemia: an effect reversible with vitamin C therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.81

Increased superoxide production in coronary arteries in hyperhomocysteinemia: role of tumor necrosis factor-alpha, NAD(P)H oxidase, and inducible nitric oxide synthase

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.81

Cellular redox state and endothelial dysfunction in mildly hyperhomocysteinemic cystathionine beta-synthase-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.81

Overexpression of cellular glutathione peroxidase rescues homocyst(e)ine-induced endothelial dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.81

Deficiency of glutathione peroxidase-1 sensitizes hyperhomocysteinemic mice to endothelial dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.81

Hyperhomocysteinemia, oxidative stress, and cerebral vascular dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.81

Hyperhomocysteinemia enhances vascular inflammation and accelerates atherosclerosis in a murine model

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.81

Atherosclerosis — An Inflammatory Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.81

Tissue factor modulates the thrombogenicity of human atherosclerotic plaques.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.81

Role of hyperhomocysteinemia in endothelial dysfunction and atherothrombotic disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.81

Hyperhomocysteinemia and its role in the development of atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.81

Venous thrombosis: the role of genes, environment, and behavior

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.81

21 January 2018

Vision loss after PDT.

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.81

Acute severe visual acuity decrease after photodynamic therapy with verteporfin: case reports from randomized clinical trials-TAP and VIP report no. 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.81

Choroidal ischemia after photodynamic therapy with verteporfin for choroidal neovascularization

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.81

Interaction between hyperhomocysteinemia and inherited thrombophilic factors in venous thromboembolism

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.81

Methylenetetrahydrofolate reductase gene C677T and A1298C polymorphisms, plasma homocysteine, folate, and vitamin B12 levels and the extent of coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.81

The 677 C/T MTHFR polymorphism is associated with essential hypertension, coronary artery disease, and higher homocysteine levels

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.81

Homocysteinemia is inversely correlated with platelet count and directly correlated with sE- and sP-selectin levels in females homozygous for C677T methylenetetrahydrofolate reductase.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.81

Mechanisms of increased vascular oxidant stress in hyperhomocys-teinemia and its impact on endothelial function

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.81

Stress and vascular responses: endothelial dysfunction via lectin-like oxidized low-density lipoprotein receptor-1: close relationships with oxidative stress

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.81

Stereospecific and redox-sensitive increase in monocyte adhesion to endothelial cells by homocysteine

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.81

Involvement of oxidative stress in NF-kappaB activation in endothelial cells treated by photodynamic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.81

Photodynamic Therapy of Subfoveal Choroidal Neovascularization in Age-related Macular Degeneration With Verteporfin

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.1.81

21 January 2018

Identifiers

DOI

10.2217/14622416.10.1.81

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19102718%20AND%20SRC:MED&resulttype=core&format=json

release_v3ulsnb4vre7vix6ac6qjvtahq

19 January 2020

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/v3ulsnb4vre7vix6ac6qjvtahq

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference